Quarterly Activities Report and Appendix 4C - June 2026
Filed with ASX · · 7 pages · English
Summary by 6ix AI
The report highlights challenges in completing an expanded clinical study of the EXO-OC test due to unsuitable samples from biobanks, while also noting improvements in diagnostic performance from previous datasets. Inoviq reported a strong cash position at the end of the quarter, with significant cash reserves available for future operations. The company is committed to advancing the EXO-OC test towards commercialization, despite setbacks in the recent study.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
In the deck
Story so far
Earlier from Inoviq
- EXO-OC algorithm and clinical study update
- Positive CAR-exosome data in ovarian cancer
- Quarterly Activities Report and Appendix 4C - March 2026
- Appendix 4D and FY26 Half Year Financial Report
- Quarterly Business Update and Appendix 4C - December 2025
Later from Inoviq
- EXO-OC Study Outcome Investor Webinar Presentation
- EXO-OC Technical Review and Commercialisation Pathway
- INOVIQ Announces Leadership Change
- Quarterly Activities Report and Appendix 4C - September 2026
- IIQ signs EXO-OC validation agreement with Sonic Healthcare
Follow Inoviq into a list and get an email when it puts out news.
Follow Inoviq